YY2 downregulation in various tumors, including colorectal, prostate, ovarian, and liver cancers, is closely associated with poor survival and prognosis.[53, 54, 55] While previous studies have revealed that YY2 can trigger ferroptosis, ultraviolet damage response, and p53‐mediated cell cycle arrest,[29, 31, 56] studies regarding its physiological and pathological functions are still very limited, and the mechanisms underlying its tumor suppressive effect have not been completely elucidated. This evidence concerns the gene TP53 and liver cancer.